



LANSEN PHARMACEUTICAL HOLDINGS LIMITED
朗生醫藥控股有限公司

(incorporated in the Cayman Islands with limited liability)

(於開曼群島註冊成立的有限公司)

(Stock code 股份代號: 503)

20 April 2023

Dear Non-registered Shareholder(s),

Notification of publication of Circular dated 20 April 2023 relating to the Share Dividend Scheme (“Current Corporate Communications”)

We hereby notify you that the Current Corporate Communications of Lansen Pharmaceutical Holdings Limited (the “Company”), in both English and Chinese, are now available on the Company’s website at www.lansen.com.cn and HKEXnews website at www.hkexnews.hk. You may access the Current Corporate Communications by clicking “Investor Relations” on the home page of the Company’s website or browsing through the HKEXnews website.

If you wish to receive a printed copy of the Current Corporate Communications, please complete the Request Form and return it to our Company’s Hong Kong branch share registrar, Link Market Services (Hong Kong) Pty Limited, by post using the pre-paid mailing label provided (if you post in Hong Kong). Otherwise, please affix appropriate postage. The printed copy of the Current Corporate Communications will be sent to you free of charge upon receipt of your request.

Please note that by completing and returning the Request Form to request for the printed copy of the Current Corporate Communications, you will expressly indicate that you prefer to receive all future Corporate Communication(s) of the Company in printed form.

Should you have any queries relating to this notification, please call the hotline of the Company’s Hong Kong branch share registrar, Link Market Services (Hong Kong) Pty Limited, at +852 3707 2600 during business hours from 9:00 a.m. to 6:00 p.m., Monday to Friday, excluding public holidays.

Yours faithfully,
For and on behalf of
Lansen Pharmaceutical Holdings Limited
Wu Zhen Tao
Chairman

Corporate Communication(s) refer to any document(s) issued or to be issued by the Company for the information or action of any holders of its securities, including but not limited to annual reports, interim reports, notice of meetings, listing documents, circulars and proxy forms.

致非登記股份持有人：

日期為二零二三年四月二十日之通函，乃有關股份股息計劃（「本次公司通訊」）之發佈通知

我司現謹通知閣下，朗生醫藥控股有限公司（「本公司」）之本次公司通訊的英文及中文版現已登載於本公司網站www.lansen.com.cn及香港交易所披露易網站瀏覽www.hkexnews.hk。請在本公司網站主頁的「投資者關係」或在香港交易所披露易網站瀏覽有關文件。

倘閣下擬收取本次公司通訊的印刷本，可填妥申請表格及利用預付郵寄標籤（如在香港投寄）寄回本公司之香港股份過戶登記分處Link Market Services (Hong Kong) Pty Limited。否則，請貼上適當的郵資。本次公司通訊的印刷本將免費發送予閣下。

請注意，當閣下填寫及寄回申請表格以索取本次公司通訊的印刷本後，即表示閣下確認擬收取本公司日後刊發的所有公司通訊的印刷本。

倘閣下對本通知有任何查詢，請於星期一至星期五（公眾假期除外）辦公時間上午九時至下午六時，致電本公司之香港股份過戶登記分處Link Market Services (Hong Kong) Pty Limited之電話熱線+852 3707 2600查詢。

朗生醫藥控股有限公司
主席
吳鎮濤
謹啟

公司通訊文件指本公司發出或將發出以供其任何證券持有人參照或採取行動之任何文件，包括但不限於年報、中期報告、會議通告、上市文件、通函及代表委任表格。

二零二三年四月二十日